The Food and Drug Administration (FDA) has approved Tagrisso (osimertinib; AstraZeneca) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
{iframe}http://www.empr.com/news/non-small-cell-lung-cancer-osimertinib-egfr-tyrosine-kinase/article/647664/{/iframe}